7934 Government Road, Burnaby,
B.C., V5A 2E2
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
The Cannabix Marijuana Breathalyzer is being developed
to give law enforcement and employers a tool to enforce public
safety
Vancouver, BC -- May 25, 2017 -- InvestorsHub NewsWire --
Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (the "Company or Cannabix") developer of the
Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased to announce that Dr. David Hasman has joined
its scientific team to initiate trials in Vancouver, British
Columbia. Dr. David Hasman is with Forensic Science and Technology
at the British Columbia Institute of Technology (BCIT) and has been
providing his expertise in the LC/MS/MS method for fentanyl and
analogues for the B.C. Provincial Toxicology Centre in
Vancouver.
Dr. Hasman received his PhD in Chemical Physics from the
University of California and was a postdoctoral fellow at the
University of British Columbia. Joining a Vancouver based
laboratory he was involved in method development for therapeutic
drug monitoring and was part of an effort to develop a mass
spectral drug library for Agriculture Canada.
After a career at Hewlett-Packard and Agilent Technologies Dr.
Hasman taught chromatographic based analysis at BCIT and University
of British Columbia. During that period, he joined BCIT Forensics
Sciences and formed Procyon Research Inc. Procyon Research is
involved in GC/MS and LC/MS/MS method development in forensics,
natural products, and environmental disciplines.
Cannabix is developing its FAIMS- (field asymmetric waveform ion
mobility spectrometry) based marijuana breathalyzer for the
detection of delta-9-tetrahydrocannabinol ("THC") in human breath.
The addition of Dr. Hasman to our Florida-Vancouver scientific
team, will broaden our testing capabilities in Vancouver with human
subjects using the Cannabix Marijuana Breathalyzer Beta prototype.
The Company is substantially increasing its testing ability with
new equipment and staff joining the Vancouver operation. Over the
last several weeks, the Company has been developing a new front end
breath intake system and calibrating decay signal intensities.
Dr. Raj Attariwala, commented, "We are excited to have Dr.
Hasman join our Vancouver team as we prepare for trials using the
patented FAIMS device with court accepted techniques of mass
spectroscopy. His expertise in toxicology and forensic mass spec
have been instrumental with government toxicology labs during the
recent fentanyl crisis in BC and his skills will be invaluable as
we prepare for trials with the Cannabix marijuana breathalyzer
device."
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects use days or even weeks earlier.
The devices will also be useful for other practical applications
such as testing employees in the workplace where intoxication by
THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Companys plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (v) the ability of the Company to develop and
market its future product; and (vi) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing patent pending technologies licensed by
the Company will receive patent status by regulatory authorities.
The Company is not currently selling commercial breathalyzers.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.